Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases

Yoshiko Yano, Junji Yamamoto, Tomoo Kosuge, Yoshihiro Sakamoto, Susumu Yamasaki, Kazuaki Shimada, Hidenori Ojima, Michiie Sakamoto, Tadatoshi Takayama, Masatoshi Makuuchi

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Background: Combined hepatocellular and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail. The aim of this study was to clarify the characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The clinicopathological features of 26 cHCC-CC patients, who were surgically treated, were reviewed by comparing them with the features of patients suffering from ordinary hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Results: The cHCC-CC patients showed greater similarity with HCC patients than with CC patients with regard to male/female ratio, status of hepatitis viral infection, serum alpha- fetoprotein (AFP) level, and non-tumor liver histology. The disease stage of the cHCC-CC patients was more advanced than that of either the HCC or CC patients. The cHCC-CC tumors were significantly more invasive to the portal vein than the HCC tumors and were comparable to the CC tumors. The overall 3-, 5-, and 10-year survival rates and the median survival times (95% confidence interval) were 34.6%, 23.1%, 11.5% and 1.8 (0.7-3.0) years for cHCC-CC patients, 86.7%, 66.2%, 46.8% and 4.6 (4.3-5.0) years for HCC patients, and 68.5%, 32.3%, 23.9% and 1.9 (1.1-2.7) years for CC patients, respectively. Survival of patients with cHCC-CC was significantly poorer than that of HCC or CC patients. Among the 26 patients, six survived for >5 years. Conclusions: In most cases, cHCC-CC seems to be a variant of ordinary HCC with cholangiocellular features, rather than a true intermediate disease entity between HCC and CC. The surgical approach is recommended for selected patients with cHCC-CC.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number6
DOIs
Publication statusPublished - 2003 Jun 1
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Hepatocellular Carcinoma
Neoplasms
Survival

Keywords

  • Combined hepatocellular and cholangiocarcinoma
  • Pathology
  • Stage
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Yano, Y., Yamamoto, J., Kosuge, T., Sakamoto, Y., Yamasaki, S., Shimada, K., ... Makuuchi, M. (2003). Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases. Japanese Journal of Clinical Oncology, 33(6), 283-287. https://doi.org/10.1093/jjco/hyg056

Combined hepatocellular and cholangiocarcinoma : A clinicopathologic study of 26 resected cases. / Yano, Yoshiko; Yamamoto, Junji; Kosuge, Tomoo; Sakamoto, Yoshihiro; Yamasaki, Susumu; Shimada, Kazuaki; Ojima, Hidenori; Sakamoto, Michiie; Takayama, Tadatoshi; Makuuchi, Masatoshi.

In: Japanese Journal of Clinical Oncology, Vol. 33, No. 6, 01.06.2003, p. 283-287.

Research output: Contribution to journalArticle

Yano, Y, Yamamoto, J, Kosuge, T, Sakamoto, Y, Yamasaki, S, Shimada, K, Ojima, H, Sakamoto, M, Takayama, T & Makuuchi, M 2003, 'Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases', Japanese Journal of Clinical Oncology, vol. 33, no. 6, pp. 283-287. https://doi.org/10.1093/jjco/hyg056
Yano, Yoshiko ; Yamamoto, Junji ; Kosuge, Tomoo ; Sakamoto, Yoshihiro ; Yamasaki, Susumu ; Shimada, Kazuaki ; Ojima, Hidenori ; Sakamoto, Michiie ; Takayama, Tadatoshi ; Makuuchi, Masatoshi. / Combined hepatocellular and cholangiocarcinoma : A clinicopathologic study of 26 resected cases. In: Japanese Journal of Clinical Oncology. 2003 ; Vol. 33, No. 6. pp. 283-287.
@article{239e4cab88754251acb6854a4c6bbca8,
title = "Combined hepatocellular and cholangiocarcinoma: A clinicopathologic study of 26 resected cases",
abstract = "Background: Combined hepatocellular and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail. The aim of this study was to clarify the characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The clinicopathological features of 26 cHCC-CC patients, who were surgically treated, were reviewed by comparing them with the features of patients suffering from ordinary hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Results: The cHCC-CC patients showed greater similarity with HCC patients than with CC patients with regard to male/female ratio, status of hepatitis viral infection, serum alpha- fetoprotein (AFP) level, and non-tumor liver histology. The disease stage of the cHCC-CC patients was more advanced than that of either the HCC or CC patients. The cHCC-CC tumors were significantly more invasive to the portal vein than the HCC tumors and were comparable to the CC tumors. The overall 3-, 5-, and 10-year survival rates and the median survival times (95{\%} confidence interval) were 34.6{\%}, 23.1{\%}, 11.5{\%} and 1.8 (0.7-3.0) years for cHCC-CC patients, 86.7{\%}, 66.2{\%}, 46.8{\%} and 4.6 (4.3-5.0) years for HCC patients, and 68.5{\%}, 32.3{\%}, 23.9{\%} and 1.9 (1.1-2.7) years for CC patients, respectively. Survival of patients with cHCC-CC was significantly poorer than that of HCC or CC patients. Among the 26 patients, six survived for >5 years. Conclusions: In most cases, cHCC-CC seems to be a variant of ordinary HCC with cholangiocellular features, rather than a true intermediate disease entity between HCC and CC. The surgical approach is recommended for selected patients with cHCC-CC.",
keywords = "Combined hepatocellular and cholangiocarcinoma, Pathology, Stage, Surgery, Survival",
author = "Yoshiko Yano and Junji Yamamoto and Tomoo Kosuge and Yoshihiro Sakamoto and Susumu Yamasaki and Kazuaki Shimada and Hidenori Ojima and Michiie Sakamoto and Tadatoshi Takayama and Masatoshi Makuuchi",
year = "2003",
month = "6",
day = "1",
doi = "10.1093/jjco/hyg056",
language = "English",
volume = "33",
pages = "283--287",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Combined hepatocellular and cholangiocarcinoma

T2 - A clinicopathologic study of 26 resected cases

AU - Yano, Yoshiko

AU - Yamamoto, Junji

AU - Kosuge, Tomoo

AU - Sakamoto, Yoshihiro

AU - Yamasaki, Susumu

AU - Shimada, Kazuaki

AU - Ojima, Hidenori

AU - Sakamoto, Michiie

AU - Takayama, Tadatoshi

AU - Makuuchi, Masatoshi

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background: Combined hepatocellular and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail. The aim of this study was to clarify the characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The clinicopathological features of 26 cHCC-CC patients, who were surgically treated, were reviewed by comparing them with the features of patients suffering from ordinary hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Results: The cHCC-CC patients showed greater similarity with HCC patients than with CC patients with regard to male/female ratio, status of hepatitis viral infection, serum alpha- fetoprotein (AFP) level, and non-tumor liver histology. The disease stage of the cHCC-CC patients was more advanced than that of either the HCC or CC patients. The cHCC-CC tumors were significantly more invasive to the portal vein than the HCC tumors and were comparable to the CC tumors. The overall 3-, 5-, and 10-year survival rates and the median survival times (95% confidence interval) were 34.6%, 23.1%, 11.5% and 1.8 (0.7-3.0) years for cHCC-CC patients, 86.7%, 66.2%, 46.8% and 4.6 (4.3-5.0) years for HCC patients, and 68.5%, 32.3%, 23.9% and 1.9 (1.1-2.7) years for CC patients, respectively. Survival of patients with cHCC-CC was significantly poorer than that of HCC or CC patients. Among the 26 patients, six survived for >5 years. Conclusions: In most cases, cHCC-CC seems to be a variant of ordinary HCC with cholangiocellular features, rather than a true intermediate disease entity between HCC and CC. The surgical approach is recommended for selected patients with cHCC-CC.

AB - Background: Combined hepatocellular and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer, the clinicopathological features of which have rarely been reported in detail. The aim of this study was to clarify the characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Methods: The clinicopathological features of 26 cHCC-CC patients, who were surgically treated, were reviewed by comparing them with the features of patients suffering from ordinary hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Results: The cHCC-CC patients showed greater similarity with HCC patients than with CC patients with regard to male/female ratio, status of hepatitis viral infection, serum alpha- fetoprotein (AFP) level, and non-tumor liver histology. The disease stage of the cHCC-CC patients was more advanced than that of either the HCC or CC patients. The cHCC-CC tumors were significantly more invasive to the portal vein than the HCC tumors and were comparable to the CC tumors. The overall 3-, 5-, and 10-year survival rates and the median survival times (95% confidence interval) were 34.6%, 23.1%, 11.5% and 1.8 (0.7-3.0) years for cHCC-CC patients, 86.7%, 66.2%, 46.8% and 4.6 (4.3-5.0) years for HCC patients, and 68.5%, 32.3%, 23.9% and 1.9 (1.1-2.7) years for CC patients, respectively. Survival of patients with cHCC-CC was significantly poorer than that of HCC or CC patients. Among the 26 patients, six survived for >5 years. Conclusions: In most cases, cHCC-CC seems to be a variant of ordinary HCC with cholangiocellular features, rather than a true intermediate disease entity between HCC and CC. The surgical approach is recommended for selected patients with cHCC-CC.

KW - Combined hepatocellular and cholangiocarcinoma

KW - Pathology

KW - Stage

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=17944402023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944402023&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyg056

DO - 10.1093/jjco/hyg056

M3 - Article

C2 - 12913082

AN - SCOPUS:17944402023

VL - 33

SP - 283

EP - 287

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

ER -